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Abstract
Background: Hepatitis C Virus (HCV) infection is a major health problem throughout world that causes acute and
chronic infection which resulted in liver fibrosis, hepatocellular carcinoma and death. The only therapy currently
available for HCV infection is the combination of pegylated interferon alpha (PEG-IFN a) and ribavirin. This therapy
can effectively clear the virus infection in only 50% of infected individuals. Hence, there is a dire need to develop
antiviral agents against HCV.
Results: This study was design to examine the ability of exogenous small interfering RNAs (siRNAs) to block the
replication of HCV in human liver cells. In the present study six 21-bp siRNAs were designed against different
regions of HCV non-structural genes (NS2, NS3 serine protease/helicase, NS4Band NS5B RNA dependent RNA
polymerase). siRNAs were labeled as NS2si241, NS3si-229, NS3si-858, NS4Bsi-166, NS5Bsi-241 and NS5Bsi-1064. We
found that siRNAs against HCV NS2- NS5B efficiently inhibit HCV replication in Huh-7 cells. Our results
demonstrated that siRNAs directed against HCV NS3 (NS3si-229 and NS3si-858) showed 58% and 88% reduction in
viral titer respectively. Moreover, NS4Bsi-166 and NS5Bsi-1064 exhibited a dramatic reduction in HCV viral RNA and
resulted in greater than 90% inhibition at a 20 μM concentration, while NS2si-241 showed 27% reduction in viral
titer. No significant inhibition was detected in cells transfected with the negative control siRNA.
Conclusion: Our results suggest that siRNAs targeting against HCV non-structural genes (NS2-NS5B) efficiently
inhibit HCV replication and combination of these siRNAs of different targets and interferon will be better option to
treat HCV infection throughout the world.
Background
HCV has infected 200 million people worldwide, of
which 10 million individuals (6% of the population) have
been spotted in Pakistan [1]. In 40-60% of HCV-infected
individuals, persistent infection is mainly associated with
liver cirrhosis and steatosis, leading to hepatocellular
carcinoma (HCC) [2,3]. About 75% of patients receive
no therapeutic benefit from the current combination
therapy with PEG-IFN a and the guanosine analog riba-
virin because of adverse side effects and high cost [4]. In
order to improve treatment outcomes, there is a dire
need to develop more effective and better therapeutic
options for treating HCV infections.
Currently, RNA interference (RNAi) has been emerged
as a potential technique for developing anti-mRNA
based therapeutics against different viral diseases such
as HPV [5], HIV [6], Yellow fever virus [7,8]. RNAi is a
sequence-specific RNA degradation process in the cyto-
plasm of eukaryotic cells triggered by double-stranded
RNA (dsRNA), widely existing in many species from
nematode to human [Fire, 1998, Elbashir, 2001, Leung,
2005,]. Upon introduction into the cells, exogenous
dsRNAs are cut into 21-25 nt small interfering RNA
(siRNA) by an RNase III-like enzyme called Dicer. The
siRNAs form RNA-induced silencing complex (RISC)
with other cellular components, and lead to the cleavage
of their homologous transcript and eventually the silen-
cing of specific gene [9-11]. HCV RNA is an attractive
target for RNAi, as the single positive-stranded viral
transcript functions both as genomic RNA and a repli-
cation template, and also because of its localization in
the infected liver, an organ that can be readily targeted
by nucleic acid molecules and viral vectors. As Dicer
and the RISC act in the cytoplasm so the cytoplasmic
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than other methods that attempt to silence genes at the
nuclear level. Several reports demonstrated that siRNAs
against HCV genomic and sub-genomic replicons inhibit
HCV replication [12-16].
HCV was firstly recognized in 1989 [17], comprising a
9.6 kb genome of positive sense. It encodes a single
large polyprotein of 3010 amino acids is translated from
the long open reading frame (ORF) encoded within the
viral RNA genome. This large protein is then cleaved
into 10 different individual proteins by the combined
action of the cellular and viral proteases. The viral core,
E1, E2, and P-7 proteins are called the structural pro-
teins required for the production of infectious virus par-
ticles, their secretion and infection. The remaining non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A,
NS5B) are essential for replication of HCV positive and
negative strand RNA [18]. Among these non-structural
proteins, HCV NS3 serine protease and NS5b RNA
dependent RNA Polymerase are important targets to
develop antiviral drugs against HCV [19,20]. The pre-
sent study was devise to study the effect of siRNAs
against HCV replication in liver infected cells. The pre-
sent study demonstrates that the RNAi-mediated silen-
cing of the HCV full length viral particle may be one of
the important therapeutic opportunities against HCV 1a
genotype.
Material methods
Serum Sample Collection
HCV-1a patient’ss e r u ms a m p l e su s e di nt h i si n v e s t i g a -
tion were obtained from the CAMB (Center for Applied
Molecular Biology) diagnostic laboratory, Lahore, Paki-
stan. Serum samples were stored at -80°C prior to viral
inoculation experiments. Quantification and genotype
was assessed by CAMB diagnostic laboratory, Lahore,
Pakistan. Patient’s written consent and approval for this
study was obtained from institutional ethics committee.
siRNA designing
Small interfering RNA oligonucleotides against HCV
non structural genes (NS2-NS5B) were designed to the
most conserved target region of these genes using the
Ambion’s siRNA design tool http://www.ambion.com/
techlib/misc/siRNA_finder.html. The designed siRNAs
against HCV non structural genes were synthesized
using Silencer siRNA construction kit according to the
manufacturer’s instruction (Ambion, USA).
Cell line
The Huh-7 cell line was compassionately offered by Dr.
Zafar Nawaz (Biochemistry and Molecular Biology
Department, University of Miami, USA). Huh-7 cells
were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum &
100 IU/ml penicillin & 100 μg/ml streptomycin, at 37°C
in an atmosphere of 5% CO2.
Anti-HCV analysis of siRNAs on Huh-7 cells
Huh-7 cell line was used to establish the in-vitro repli-
cation of HCV. A similar protocol was used for viral
inoculation as established by Zekari et al. 2009 [21] and
El-Awardy et al. 2006 [22]. High viral titer >1 × 10
8 IU/
ml from HCV-1a patient’s was used as principle inocu-
lum in these experiments. Huh-7 cells were maintained
in 6-well culture plates to semi-confluence, washed
twice with serum-free medium, then inoculated with
500 μl( 5×1 0
7IU/well) and 500 μl serum free media.
Cells were maintained overnight at 37°C in 5% CO2.
Next day, adherent cells were washed three times with 1
× PBS, complete medium was added and incubation was
continued for 48 h. Cells were harvested and assessed
for viral RNA quantification by Real Time PCR. To ana-
lyze the effect of siRNAs on HCV infection, serum
infected Huh-7 cells were again seeded after three days
of infection in 24-well plates in the presence and
absence of siRNAs and grown to 80% confluence. After
72 h, total RNA was isolated by using Gentra RNA iso-
lation kit (Gentra System Pennsylvania, USA) according
to the manufacturer’s instructions. Briefely, cells were
lysed with cell lysis solution containing 5 μl internal
control (Sacace Biotechnologies Caserta, Italy). RNA pal-
let was solubilized in 1% DEPC (Diethyl pyrocarbonate
treated water). HCV RNA quantifications were deter-
mined by Real Time PCR Smart Cycler II system (Cep-
heid Sunnyvale, USA) using the Sacace HCV
quantitative analysis kit (Sacace Biotechnologies Caserta,
Italy) according to the manufacturer’s instructions.
Formula for the calculation of HCV RNA concentration
Following formula was used to calculate the concentra-
tion HCV RNA of each sample.
Cy3STD/Res
Fam. STD/Res
× coefﬁcient IC = IU HCV/mL
IC = internal control, which is specific for each lot.
Statistical Analysis
All statistical analysis was done using SPSS software
(version 11.0, SPSS Inc). Data is presented as mean +
SE. Numerical data was analyzed using student’st - t e s t
and ANOVA. P value < 0.05 was considered statistically
significant.
Results
The ability of siRNAs to inhibit HCV replication were
evaluated by designing and constructing siRNAs against
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type 1a (NS2, NS3, NS4B and NS5B). siRNA targeting
sites were selected in regions conserved among different
samples. Selected siRNAs were labeled as NS2si-241,
NS3si-229, NS3si-858, NS4Bsi-166, NS5Bsi-241 and
NS5Bsi-1065. The negative control siRNA was also
included which has the same nucleotide composition as
the experimental siRNA, but the sequence has been
scrambled so that it does not has the significant sequence
homology to with the HCV genes. The DNA olio tem-
plates were ordered from Sigma (Sigma Aldrich U.S.A.)
(Table 1). We speculated that siRNAs design against HCV
non-structural genes has the ability to inhibit the replica-
tion of HCV. To test this possibility, Huh-7 serum infected
cells were treated with synthetic siRNAs and subsequently
incubated for 3 days. Real time results showed that siR-
NAs targeted against non- structural genes inhibit HCV
replication different from each other. siRNAs directed
against HCV NS3 serine protease/helicase (NS3si-229 and
NS3si-858) resulted in 58% and 82% reduction in viral
titer, while siRNA against HCV NS2 gene (NS2si-241)
showed 27% reduction in viral titer. siRNAs aginst HCV
NS5B RNA dependent RNA polymerase and NS4B genes
showed a dramatic reduction in HCV viral RNA, NS4Bsi-
166 and NS5Bsi-1064 exhibited maximum inhibition up to
90% at a 20 μM concentration. No significant inhibition
was detected in cells transfected with the negative control
siRNA (Figure[1]). This result was in accordance with
Zekri et al. 2009 [21] who also showed best inhibitory
effect of siRNAs against 5’UTR on 3rd day of post-trans-
fection. Together, these data suggest that siRNA targeted
against HCV non-structural genes inhibit HCV repliction.
Discussion
With the progress in advanced technologies, RNAi has
not only become a powerful tool for studying gene func-
tion and development of gene-based therapies, but also
been widely used to inhibit viral replication of viruses
such as HIV [6], HBV [12], HCV [12], respiratory
viruses [23]. Previous reports showed that, at the mole-
cular, cellular and individual levels, RNAi can potentially
be used to block viral transmission and thus prevent the
viral diseases [24]. With the high efficiency, specificity
and low cytotoxicity, RNAi offered a new promise of
anti-viral therapy.
Huh-7 and its derived cell lines are the most widely
used cell culture systems for liver-associated diseases and
the development of antiviral agents against HCV [25-27].
Guha et al. reported that in-vitro cell culture models can
demonstrate the infectivity of the virus and can be used
for evaluating drugs for antiviral activity or inhibition of
HCV infection [28]. Recently different groups have stu-
died the HCV replication in serum infected liver cell
lines which mimics the naturally occurring HCV virions
biology and kinetics of HCV infection in human. We
infected Huh-7 cells with native viral particles from
HCV-1a positive serum using the same protocol as
describe by El-Awady et al., and Zekri et al [21,22].
Previous reports have demonstrated that NS3 and
NS5B is essential for viral replication and therefore, pro-
vides an attractive target for development of antiviral
agents [29-31]. In this study, we showed that siRNAs
can be used as a potent approach to reduce HCV repli-
cation in a sequence-specific manner. We screened six
siRNAs targeting conserved region of HCV non- struc-
tural genes and examined their effect on viral replica-
tion. An exciting finding of this study is decline of HCV
viral titer to a maximum of 90% with a gene specific
siRNAs directed against HCV NS5B RNA dependent
Table 1 Sequence of siRNA oligonucleotides directed
against HCV 1a non-structural genes
SN siRNAs Name Sequence 5’-3’
1 NS2si 241-antisense AAACTACTCCTGGCCATCTTCCCTGTCTC
2 NS2si 241-sense AAGAAGATGGCCAGGAGTAGTCCTGTCTC
3 NS3si 229-antisense AATGTGGACCAAGACCTTGTGCCTGTCTC
4 NS3si 229-sense AACACAAGGTCTTGGTCCACACCTGTCTC
5 NS3si 858-antisense AATAATTTGTGACGAGTGCCACCTGTCTC
6 NS3si 858-sense AATGGCACTCGTCACAAATTACCTGTCTC
7 NS4Bsi 166-antisense AATTTCATCAGTGGGATACAACCTGTCTC
8 NS4Bsi 166-sense AATTGTATCCCACTGATGAAACCTGTCTC
9 NS5Bsi 241-antisense AACTTGCTATCCGTAGAGGAACCTGTCTC
10 NS5Bsi 241-sense AATTCCTCTACGGATAGCAAGCCTGTCTC
11 NS5Bsi 1064-antisense AACCAGAATACGACTTGGAGCCCTGTCTC
12 NS5Bsi 1064-sense AAGCTCCAAGTCGTATTCTGGCCTGTCTC
Figure 1 Antiviral effect of siRNAs against HCV viral replication.
Huh-7 cells were infected with high titer sera sample from HCV-1a
patients to establish in vitro cell culture model of HCV-1a, cells were
maintained overnight at 37°C in 5% CO2 for three days. Cells were
harvested after siRNA treatment 48 hrs post transfection and
intracellular HCV RNA levels were quantified by Real Time PCR. Data
is expressed as percentage of HCV survival in cells. Error bars
indicate, mean S.D p < 0.05 verses control.
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Huh-7 cells was observed through detection of 5’UTR of
viral copies by Real Time PCR in cells 3rd day post
infection. HCV NS3si-229 and NS5Bsi-241 showed
greater than 50% inhibition in viral titer, while NS2si-
241 exhibited only 27% reduction in viral titer. Other
investigators have also reported the inhibition of HCV
replication by targeting NS5A, NS3, or NS5B sequences
[13,15,32,33]. Our data suggest that effect of siRNAs
against HCV non- structural genes on HCV viral titer
reduction is possibly due to the simultaneous degrada-
tion of HCV genomic RNA (as HCV genome contains a
positive sense ssRNA).
In summary, these results clearly show that the siR-
NAs mediated viral gene silencing is a very effective
antiviral strategy that has a very strong potential for cur-
ing chronic hepatitis C virus infection.
Abbreviations
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